- Home
- FENC vs EDIT Comparison
FENC vs EDIT Comparison
Compare FENC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | EDIT |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.0M | 432.8M |
| IPO Year | 2010 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FENC | EDIT |
|---|---|---|
| Price | $10.71 | $2.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $17.67 | $6.10 |
| AVG Volume (30 Days) | 128.3K | ★ 2.5M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $44,642,000.00 | $31,937,000.00 |
| Revenue This Year | $62.55 | N/A |
| Revenue Next Year | $42.10 | N/A |
| P/E Ratio | $177.17 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $5.65 | $1.66 |
| 52 Week High | $13.25 | $4.33 |
Technical Indicators
Market Signals| Indicator | FENC | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 56.18 |
| Support Level | $9.84 | $2.46 |
| Resistance Level | $11.29 | $3.18 |
| Average True Range (ATR) | 0.50 | 0.19 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 56.54 | 70.14 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.